166.66BMarket Cap-63934P/E (TTM)
29.590High28.453Low36.56MVolume28.540Open28.560Pre Close1.07BTurnover0.65%Turnover Ratio79.49P/E (Static)5.67BShares32.21952wk High1.90P/B166.42BFloat Cap24.48052wk Low1.66Dividend TTM5.66BShs Float54.716Historical High5.64%Div YieldTTM3.98%Amplitude5.477Historical Low29.291Avg Price1Lot Size
ThirtyOne : Agreed. It’s hard to even fathom the standards of being overvalued in this generation.
QMengColdJoke : if oral GLP-1 is good to go… Short LLY. Really fat people (fat cells doesn’t fell pain) and people with diabetes (get used to) don’t care to have needle hole. But think about 25 to 30 BMI people, Having needle holes would really be a concern
MonkeyGee OP QMengColdJoke : please explain. I don't trade based on company activities but based on stock trends.
QMengColdJoke MonkeyGee OP : Zepbound is much better than Wegovy/Ozempic in effectiveness. They used to have similar price like 1000 per month. Typically insurance only cover a ratio. LLY recently cuts to 400 to 600 per month. Liraglutide will be out of patent pretty soon that people can manufacture (but cannot sell as drug) That would cut revenue projection…
QMengColdJoke MonkeyGee OP : LLY is a great company. But wall street has made stock price way too expensive.